Trial record 13 of 528 for:    "Migraine Disorders"

Preventive Treatment of Episodic and Chronic Migraine

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by California Medical Clinic for Headache.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
California Medical Clinic for Headache
ClinicalTrials.gov Identifier:
NCT01319825
First received: March 18, 2011
Last updated: NA
Last verified: March 2011
History: No changes posted
  Purpose

This is an open label pilot study to determine whether milnacipran can reduce headache frequency in episodic and chronic migraine sufferers.


Condition Intervention Phase
Migraine With Aura
Migraine Without Aura
Chronic Migraine
Drug: milnacipran
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine.

Resource links provided by NLM:


Further study details as provided by California Medical Clinic for Headache:

Primary Outcome Measures:
  • Reduction in number of all headache days per month in the last month of stable dosing, compared to baseline [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reduction in number of migraine days per month in the last month of stable dosing compared to baseline. [ Time Frame: 4 months ] [ Designated as safety issue: No ]
  • Improvement in headache index score [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    Headache index is defined by headache severity x headache duration.

  • Reduction in the number of days of headache related disability/impairment [ Time Frame: 4 months ] [ Designated as safety issue: No ]
  • Tolerability [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
    Assessment of adverse events

  • Use of rescue medications [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    To assess the continued need for acute headache treatments during the study period.

  • Quality of life measures [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 45
Study Start Date: April 2011
Estimated Study Completion Date: July 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: milnacipran
    100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
Detailed Description:

Patients with episodic migraine with and/or without aura and chronic migraine will be treated with 100 or 200 mg of milnacipran for a total of 4 months including a one month titration phase and a 3 month maintenance phase. Baseline (pre-treatment) and end-of-maintenance phase headache frequencies will be recorded. There is no placebo treatment in this study. In addition to headache frequencies, other parameters being measured include safety and tolerability.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Migraine with or without aura or chronic migraine.
  • Subject age 18 to 70.
  • At least 2 migraine attacks per month.
  • Willing ang able to give written informed consent.
  • Willing and able to complete the entire course of the study and to comply with study instructions.
  • Willing to taper and discontinue their current preventive medications.

Exclusion Criteria:

  • Subject is pregnant, lactating or planning a pregnancy in the next year.
  • Subject is female of child-bearing potential and not taking adequate forms of birth control.
  • Significant medical or psychiatric disease or abnormal laboratory data that would preclude entry into this study.
  • Previous failure of four or more adequate trials of preventive medication.
  • Currently on any form of antidepressant for depression and not able to discontinue.
  • Currently demonstrating medication overuse headache.
  • Currently has uncontrolled narrow angle glaucoma.
  • Currently taking monoamine oxidase inhibitors.
  • Subject has a history of seizures.
  • Participation in an investigational drug study within the last 30 days or 5 half-lives, whichever is longer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01319825

Contacts
Contact: David B Kudrow, MD 310-315-1456 dbkudrow@earthlink.net

Locations
United States, California
California Medical Clinic for Headache Not yet recruiting
Santa Monica, California, United States, 90404
Contact: Tatyana Neyman, MD    310-315-1456    tneyman@drkudrow.com   
Sub-Investigator: Alan Rapoport, MD         
Sponsors and Collaborators
California Medical Clinic for Headache
Investigators
Principal Investigator: David B Kudrow, MD California Medical Clinic for Headache
  More Information

Additional Information:
No publications provided by California Medical Clinic for Headache

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: David Kudrow, M.D., California Medical Clinic for Headache
ClinicalTrials.gov Identifier: NCT01319825     History of Changes
Other Study ID Numbers: SAV-MD-26
Study First Received: March 18, 2011
Last Updated: March 18, 2011
Health Authority: United States: Food and Drug Aministration.

Additional relevant MeSH terms:
Migraine Disorders
Migraine with Aura
Migraine without Aura
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Milnacipran
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Adrenergic Agents

ClinicalTrials.gov processed this record on August 20, 2014